Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need
Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment
The product will be marketed under store brand labels and is comparable to the brand Zyrtec
Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
IIRSI 2021 aims to bring together ophthalmologists across India and abroad to discuss the advancement in technology and their experience in IOL implantation and Refractive Surgery
Subscribe To Our Newsletter & Stay Updated
